Abstract 3660: Plasma cell free DNA hydroxymethylation profiling reveals anti-PD1 treatment response and resistance biology in non-small cell lung cancer

Abstract

Abstract Background: Treatment with immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1) can yield durable anti-tumor responses, yet not all patients respond to ICIs. Current approaches to select patients who may benefit from anti-PD-1 treatment are insufficient. 5-hydroxymethylation (5hmC) analysis of plasma-derived cell free DNA (cfDNA) presents a novel non-invasive approach for identification of therapy response biomarkers which can tackle challenges associated with tumor biopsies such as tumor heterogeneity and serial sample collection. Methods: 151 blood samples were collected from 31 non-small cell lung cancer (NSCLC) patients before therapy start and at multiple timepoints whilst on therapy. Blood samples were processed to obtain plasma-derived cfDNA, followed by enrichment of 5hmC-containing cfDNA fragments through biotinylation via a two-step chemistry and binding to streptavidin coated beads. 5hmC-enriched cfDNA and whole genome libraries were prepared in parallel and sequenced to obtain whole hydroxymethylome and whole genome plasma profiles, respectively. Results: Comparison of on-treatment timepoint to matched pre-treatment samples from same patients revealed that anti-PD-1 treatment induced distinct changes in plasma cfDNA 5hmC profiles of responders, as judged by RECIST, relative to non-responders. In responders, 5hmC accumulated over genes involved in immune activation such as IFNγ and IFNα response, inflammatory response, and TNFα signaling, whereas in non-responders 5hmC increased over epithelial to mesenchymal transition genes. The Molecular Response to anti-PD-1 treatment, as measured by 5hmC changes in plasma cfDNA profiles were observed early, starting with the first cycle of treatment. Comparison of pre-treatment plasma samples revealed that anti-PD-1 treatment response- and resistance-associated genes can be captured by 5hmC profiling of plasma-derived cfDNA. Conclusions: These results demonstrate that 5hmC profiling can identify response and resistance associated biological pathways in plasma samples, offering a novel method for non-invasive prediction and monitoring of immunotherapy response in NSCLC. Citation Format: Gulfem D. Guler, Yuhong Ning, Ceyda Coruh, Tierney Phillips, Maryam Nabiyouni, Kyle Hazen, Aaron Scott, Wayne Volkmuth, Samuel Levy. Plasma cell free DNA hydroxymethylation profiling reveals anti-PD1 treatment response and resistance biology in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3660.